Indonesia's long-standing 100% dependence on imported plasma derivatives is about to change. Through the Indonesia Investment Authority (INA), Indonesia is partnering with SK Plasma, a subsidiary of South Korea's SK Group, to build the country's first and Southeast Asia's largest plasma-derived medicinal product (PDMP) fractionation plant, which is expected to end the complete reliance on imports.
INA's Vice President for ESG affairs stated that previously all of Indonesia's plasma needs were met through imports. The jointly built plant, located in the Karawang International Industrial Park, is scheduled to start operations in the fourth quarter of 2026, with an annual processing capacity of 600,000 liters of plasma, producing plasma-derived drugs (PODP) such as albumin and immunoglobulins. The project is being advanced by a joint venture company, PT SKPlasma Core Indonesia, established by INA and SK Plasma (investment agreement signed on November 14, 2024), with INA as the second-largest shareholder. This also marks the first time a Korean company has successfully attracted INA investment.
SK Plasma has obtained a permit from the Ministry of Health to conduct PDMP business and establish the joint venture. Once completed, the plant will not only ensure the supply of essential drugs like albumin for emergency and surgical procedures but will also transform Indonesia from a "market" into a "producer country", achieving self-sufficiency in plasma derivatives. During the construction period, SK Plasma will ensure supply through a contract manufacturing organization (CMO) model: Indonesia will supply plasma from its domestic donors to the Andong plant in South Korea, and the resulting PDMP will be sold back to Indonesia; at the same time, initial training will be provided to local Indonesian workers to accelerate production stability.
Plasma, a pale yellow liquid that is 92% water in blood, plays key roles such as transporting cellular waste to the liver and kidneys for excretion and maintaining body temperature. Its fractionation products are crucial for medical treatment. This collaboration leverages SK Plasma's advantages in PDMP plant operations and technology while also reflecting Indonesia's commitment to achieving national self-reliance in the healthcare sector.
Indonesia's long-standing 100% dependence on imported plasma derivatives is about to change. Through the Indonesia Investment Authority (INA), Indonesia is partnering with SK Plasma, a subsidiary of South Korea's SK Group, to build the country's first and Southeast Asia's largest plasma-derived medicinal product (PDMP) fractionation plant, which is expected to end the complete reliance on imports.
INA's Vice President for ESG affairs stated that previously all of Indonesia's plasma needs were met through imports. The jointly built plant, located in the Karawang International Industrial Park, is scheduled to start operations in the fourth quarter of 2026, with an annual processing capacity of 600,000 liters of plasma, producing plasma-derived drugs (PODP) such as albumin and immunoglobulins. The project is being advanced by a joint venture company, PT SKPlasma Core Indonesia, established by INA and SK Plasma (investment agreement signed on November 14, 2024), with INA as the second-largest shareholder. This also marks the first time a Korean company has successfully attracted INA investment.
SK Plasma has obtained a permit from the Ministry of Health to conduct PDMP business and establish the joint venture. Once completed, the plant will not only ensure the supply of essential drugs like albumin for emergency and surgical procedures but will also transform Indonesia from a "market" into a "producer country", achieving self-sufficiency in plasma derivatives. During the construction period, SK Plasma will ensure supply through a contract manufacturing organization (CMO) model: Indonesia will supply plasma from its domestic donors to the Andong plant in South Korea, and the resulting PDMP will be sold back to Indonesia; at the same time, initial training will be provided to local Indonesian workers to accelerate production stability.
Plasma, a pale yellow liquid that is 92% water in blood, plays key roles such as transporting cellular waste to the liver and kidneys for excretion and maintaining body temperature. Its fractionation products are crucial for medical treatment. This collaboration leverages SK Plasma's advantages in PDMP plant operations and technology while also reflecting Indonesia's commitment to achieving national self-reliance in the healthcare sector.